

117TH CONGRESS  
1ST SESSION

# S. 1462

To amend the Federal Food, Drug, and Cosmetic Act to simplify the generic drug application process.

---

IN THE SENATE OF THE UNITED STATES

APRIL 29, 2021

Mr. CASSIDY (for himself and Ms. SMITH) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To amend the Federal Food, Drug, and Cosmetic Act to simplify the generic drug application process.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Simplifying the Ge-  
5 neric Drug Application Process Act”.

6 **SEC. 2. SUBMISSION FOR SUITABILITY.**

7 Subparagraph (C) of section 505(j)(2) of the Federal  
8 Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(2)) is  
9 amended to read as follows:

1       “(C) SUBMISSION FOR SUITABILITY DETERMINA-  
2 TIONS.—

3               “(i) IN GENERAL.—A person may submit an  
4 abbreviated application for a new drug that has a  
5 different dosage form or strength from that of a list-  
6 ed drug.

7               “(ii) SECRETARY’S DETERMINATION ON SUB-  
8 MISSION.—The Secretary shall approve or dis-  
9 approve the submission of such an abbreviated appli-  
10 cation during the course of its determination wheth-  
11 er to receive the application pursuant to section  
12 314.101 of title 21, Code of Federal Regulations (or  
13 any successor regulations).

14               “(iii) APPROVAL OF SUBMISSION.—The Sec-  
15 retary shall approve the submission of such an ab-  
16 breviated application, provided the application is oth-  
17 erwise determined to be eligible to be received, un-  
18 less the Secretary finds that—

19                       “(I) clinical investigations are required to  
20 be conducted to show the safety and effective-  
21 ness of the drug or of any of its dosage forms  
22 or strengths which differ from the listed drug;  
23 or

24                       “(II) any of the proposed changes from the  
25 listed drug would jeopardize the safe or effec-

1           tive use of the product so as to necessitate sig-  
2           nificant labeling changes to address the newly  
3           introduced safety or effectiveness problem.

4           “(iv) DISAPPROVAL OF SUBMISSION.—If the  
5           Secretary disapproves the submission of an abbre-  
6           viated application under this subparagraph, the ap-  
7           plication shall be considered not to have been re-  
8           ceived within the meaning of paragraph (5)(A).”.

○